Abstract CT238: Phase III randomized, placebo controlled trial of COX-2 inhibition in addition to standard chemotherapy for advanced non-small cell lung cancer (NSCLC):CALGB 30801 (Alliance)


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Edelman, MJ; Wang, X; Hodgson, L; Cheney, RT; Baggstrom, M; Sachdev, T; Gajra, A; Bertino, E; Reckamp, K; Molina, J; Schiller, J; Mitchell-Richards, K; Friedman, P; Ritter, J; Vokes, E

Published Date

  • October 1, 2014

Published In

  • Clinical Trials

Published By

Digital Object Identifier (DOI)

  • 10.1158/1538-7445.am2014-ct238

Conference Name

  • Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA